SG11201500980WA - Clostridium difficile polypeptides as vaccine - Google Patents

Clostridium difficile polypeptides as vaccine

Info

Publication number
SG11201500980WA
SG11201500980WA SG11201500980WA SG11201500980WA SG11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA
Authority
SG
Singapore
Prior art keywords
vaccine
clostridium difficile
polypeptides
difficile polypeptides
clostridium
Prior art date
Application number
SG11201500980WA
Inventor
Cesira Galeotti
Rosanna Leuzzi
Mariagrazia Pizza
Maria Scarselli
Meera Unnikrishnan
Manuele Martinelli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201500980WA publication Critical patent/SG11201500980WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
SG11201500980WA 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine SG11201500980WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
SG11201500980WA true SG11201500980WA (en) 2015-04-29

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500980WA SG11201500980WA (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Country Status (13)

Country Link
US (1) US9932374B2 (en)
EP (1) EP2897637A1 (en)
JP (1) JP2015529677A (en)
KR (1) KR20150056540A (en)
CN (1) CN104582722A (en)
AU (1) AU2013319821A1 (en)
BR (1) BR112015004629A2 (en)
CA (1) CA2882620A1 (en)
IL (1) IL237172A0 (en)
MX (1) MX2015002485A (en)
RU (1) RU2015106916A (en)
SG (1) SG11201500980WA (en)
WO (1) WO2014045226A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2699587T3 (en) 2011-04-22 2019-08-05 Wyeth Llc Compositions related to a mutant-clostridium difficile toxin and methods thereof
BR122016023101B1 (en) 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
EP3271375B1 (en) * 2015-02-19 2021-02-24 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2019243307A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
AU2001249345A1 (en) * 2000-03-21 2001-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
EP1292686A1 (en) * 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
CA2693958A1 (en) 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
BRPI0906060A2 (en) * 2008-02-28 2015-12-01 3M Innovative Properties Co isolated antibodies, methods of preparing an anti-clostridium difficile antibody, composition and method for detecting the presence of a clostridium difficile spore in a sample
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
AU2010325992A1 (en) * 2009-12-02 2012-05-31 Tufts University Atoxic recombinant holotoxins of Clostridium difficile as immunogens
BR112014013876A2 (en) * 2011-12-08 2019-09-24 Novartis Ag clostridium difficile toxin-based vaccine

Also Published As

Publication number Publication date
US9932374B2 (en) 2018-04-03
AU2013319821A1 (en) 2015-02-26
EP2897637A1 (en) 2015-07-29
WO2014045226A1 (en) 2014-03-27
MX2015002485A (en) 2015-06-05
JP2015529677A (en) 2015-10-08
BR112015004629A2 (en) 2017-11-21
KR20150056540A (en) 2015-05-26
CN104582722A (en) 2015-04-29
US20150315248A1 (en) 2015-11-05
CA2882620A1 (en) 2014-03-27
IL237172A0 (en) 2015-04-30
RU2015106916A (en) 2016-11-10

Similar Documents

Publication Publication Date Title
IL291571A (en) Cx3cr1-binding polypeptides
EP2807186A4 (en) Vaccines against clostridium difficile comprising recombinant toxins
GB201218427D0 (en) Blender
PL2647387T3 (en) Vaccine Composition
EP2857033A4 (en) Skin-permeating peptide
GB201220474D0 (en) Polypeptides
HK1202805A1 (en) Clostridium difficile antigens
EP2804192A4 (en) Limit switch
IL232957A0 (en) Clostridium difficile toxin-based vaccine
HK1216999A1 (en) Antibodies against clostridium difficile
SG11201500980WA (en) Clostridium difficile polypeptides as vaccine
EP2812347A4 (en) Autophagy-inducing peptide
EP2804194A4 (en) Limit switch
GB201711697D0 (en) Blender
HK1209138A1 (en) Peptides
GB201204868D0 (en) Peptides
IL237571A0 (en) Tiotropium preparations
GB201223114D0 (en) Novel peptide
HK1203416A1 (en) Novel clostridium difficile dna vaccine dna
PT2891663T (en) Psf1-derived peptides
IL231661A0 (en) Clostridium difficile antibodies
GB201121149D0 (en) Clostridium difficile toxin-based vaccine
DK2846829T3 (en) Vaccine combinations
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides